FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W346407400> ?p ?o ?g. }

• W346407400 startingPage "485" @default.
• W346407400 abstract "Writing in the August issue of the newsletter of the Drug, Device and Biotech Committee, James A. O'Neal and Amy R. Freestone of the Minneapolis office of Faegre & Benson, tell the story of dismissal: Considerable publicity has been generated concerning a series of class actions commenced in 2000 involving attention deficit/hyperactivity disorder (ADHD) and the medication Ritalin[R]. Within a little more than a year, four of the five class actions have been dismissed. This note looks at one aspect of one of those dismissals, the interesting application of California's anti-SLAPP statute (Strategic Lawsuits Against Public Participation) to a Ritalin[R] class action. In September of 2000, a group of plaintiffs' attorneys commenced an action in federal court in the Southern District of California against Novartis Pharmaceuticals Corp. and its predecessor Ciba-Geigy, as well as two non-profit corporations, the American Psychiatric Association (APA) and the support group CH.A.D.D. (CHildren and adults with Attention Deficit Disorder). They asserted various claims centered on Novartis's supposed participation with the APA in the creation of ADHD and the establishment of the diagnostic criteria for the conditions found in the APA's Diagnostic and Statistical Manual of Mental Disorders. This case was the third in a series of class actions brought by the same attorneys in both Texas and New Jersey. All the defendants moved simultaneously to strike plaintiff's the claims pursuant to California's anti-SLAPP statute, which is Section 425.16 of the California Code of Civil Procedure, on the ground that the plaintiffs could not demonstrate a probability of prevailing on their claims. The defendants' successful application of the statute defeated the plaintiffs' claims and won dismissal of the case. The dismissal also was based on the plaintiffs' failure to plead a cognizable claim under Rules 9(b) and 12(b)(6) of the Federal Rules of Civil procedure, but this note will not address that issue. Anti-SLAPP applies The plaintiffs' claims against Novartis fell squarely within both the language and the spirit of the anti-SLAPP statute, as they arose directly from Novartis's protected speech concerning what even the plaintiffs recognized is a serious issue of public interest concerning the health of children: the diagnosis and treatment of ADHD. Both the circumstances of the California litigation and the history of the legal assault on Ritalin[R] by these plaintiffs' attorneys also demonstrate that the suit was just one more effort to produce through harassment and innuendo a result that they could not achieve through reasoned scientific consensus. The anti-SLAPP statute provides protection against suit based on any statement made in a public forum on a matter of public interest, or `conduct in furtherance of the exercise of the constitutional right ... of free speech in connection with a public issue or an issue of public interest.' Rogers v. Home Shopping Network, 57 F.Supp. 2d 973, 976 (C.D. Cal. 1999). The protection is not limited to tort actions. Church of Scientology v. Wollersheim, 49 Cal.Rptr.2d 620, 634 (Cal.App. 1996). That a speaker may have a financial or commercial interest in the subject matter of the speech does not deprive the speaker of the statute's protection. See, e.g., DuPont Merck Pharmaceutical Co. v. Superior Court, 92 Cal.Rptr.2d 755 (Cal.App. 2000) (applying anti-SLAPP statute to protect pharmaceutical company engaged in lobbying, advertising, marketing and public relations activities concerning generic equivalents of its drug). Moreover, only the issue under discussion need be of public interest. The activities on which the claims are based need not be public for the anti-SLAPP statute to apply, and in fact the statute protects even private conversations. See, e.g., Macias v. Hartwell 55 Cal.App.4th 669, 674 (1997) (private conversations protected). …" @default.
• W346407400 created "2016-06-24" @default.
• W346407400 creator A5067618671 @default.
• W346407400 creator A5081544287 @default.
• W346407400 date "2001-10-01" @default.
• W346407400 modified "2023-09-28" @default.
• W346407400 title "California Anti-SLAPP Statute Defeats Drug Class Actions" @default.
• W346407400 hasPublicationYear "2001" @default.
• W346407400 type Work @default.
• W346407400 sameAs 346407400 @default.
• W346407400 citedByCount "0" @default.
• W346407400 crossrefType "journal-article" @default.
• W346407400 hasAuthorship W346407400A5067618671 @default.
• W346407400 hasAuthorship W346407400A5081544287 @default.
• W346407400 hasConcept C11413529 @default.
• W346407400 hasConcept C144024400 @default.
• W346407400 hasConcept C17319257 @default.
• W346407400 hasConcept C17744445 @default.
• W346407400 hasConcept C199539241 @default.
• W346407400 hasConcept C2776003135 @default.
• W346407400 hasConcept C2776687834 @default.
• W346407400 hasConcept C2780858371 @default.
• W346407400 hasConcept C41008148 @default.
• W346407400 hasConcept C48103436 @default.
• W346407400 hasConcept C538833194 @default.
• W346407400 hasConcept C71924100 @default.
• W346407400 hasConcept C97460637 @default.
• W346407400 hasConceptScore W346407400C11413529 @default.
• W346407400 hasConceptScore W346407400C144024400 @default.
• W346407400 hasConceptScore W346407400C17319257 @default.
• W346407400 hasConceptScore W346407400C17744445 @default.
• W346407400 hasConceptScore W346407400C199539241 @default.
• W346407400 hasConceptScore W346407400C2776003135 @default.
• W346407400 hasConceptScore W346407400C2776687834 @default.
• W346407400 hasConceptScore W346407400C2780858371 @default.
• W346407400 hasConceptScore W346407400C41008148 @default.
• W346407400 hasConceptScore W346407400C48103436 @default.
• W346407400 hasConceptScore W346407400C538833194 @default.
• W346407400 hasConceptScore W346407400C71924100 @default.
• W346407400 hasConceptScore W346407400C97460637 @default.
• W346407400 hasIssue "4" @default.
• W346407400 hasLocation W3464074001 @default.
• W346407400 hasOpenAccess W346407400 @default.
• W346407400 hasPrimaryLocation W3464074001 @default.
• W346407400 hasRelatedWork W1492145993 @default.
• W346407400 hasRelatedWork W149686453 @default.
• W346407400 hasRelatedWork W2270573310 @default.
• W346407400 hasRelatedWork W2396624861 @default.
• W346407400 hasRelatedWork W2511950688 @default.
• W346407400 hasRelatedWork W2572969480 @default.
• W346407400 hasRelatedWork W2592937413 @default.
• W346407400 hasRelatedWork W2608755477 @default.
• W346407400 hasRelatedWork W293387767 @default.
• W346407400 hasRelatedWork W305732082 @default.
• W346407400 hasRelatedWork W3121280841 @default.
• W346407400 hasRelatedWork W3155339059 @default.
• W346407400 hasRelatedWork W318549974 @default.
• W346407400 hasRelatedWork W321045598 @default.
• W346407400 hasRelatedWork W336402353 @default.
• W346407400 hasRelatedWork W390008185 @default.
• W346407400 hasRelatedWork W853427604 @default.
• W346407400 hasRelatedWork W172940862 @default.
• W346407400 hasRelatedWork W20796830 @default.
• W346407400 hasRelatedWork W218022826 @default.
• W346407400 hasVolume "68" @default.
• W346407400 isParatext "false" @default.
• W346407400 isRetracted "false" @default.
• W346407400 magId "346407400" @default.
• W346407400 workType "article" @default.